179 related articles for article (PubMed ID: 24967525)
1. Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.
Vegter S; Oosterhof P; van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):722-32. PubMed ID: 24967525
[TBL] [Abstract][Full Text] [Related]
2. Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence.
van Boven JF; Stuurman-Bieze AG; Hiddink EG; Postma MJ; Vegter S
J Manag Care Spec Pharm; 2014 Aug; 20(8):786-92. PubMed ID: 25062071
[TBL] [Abstract][Full Text] [Related]
3. Proactive pharmaceutical care interventions improve patients' adherence to lipid-lowering medication.
Stuurman-Bieze AG; Hiddink EG; van Boven JF; Vegter S
Ann Pharmacother; 2013 Nov; 47(11):1448-56. PubMed ID: 24259595
[TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
[TBL] [Abstract][Full Text] [Related]
5. Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication.
Stuurman-Bieze AG; Hiddink EG; van Boven JF; Vegter S
Osteoporos Int; 2014 Jun; 25(6):1807-12. PubMed ID: 24570297
[TBL] [Abstract][Full Text] [Related]
6. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California.
Yu J; Shah BM; Ip EJ; Chan J
J Manag Care Pharm; 2013 Mar; 19(2):102-14. PubMed ID: 23461426
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
Hirsch JD; Rosenquist A; Best BM; Miller TA; Gilmer TP
J Manag Care Pharm; 2009; 15(1):32-41. PubMed ID: 19125548
[TBL] [Abstract][Full Text] [Related]
8. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
9. Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.
Carlton R; Coppolecchia R; Khalaf-Gillard K; Lennert B; Moradi A; Williamson T; Cameron J
J Manag Care Spec Pharm; 2018 Nov; 24(11):1102-1111. PubMed ID: 30362916
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.
Soini E; Virtanen O; Väätäinen S; Briere JB; Bowrin K; Millier A
Adv Ther; 2020 Jul; 37(7):3348-3369. PubMed ID: 32519113
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
[TBL] [Abstract][Full Text] [Related]
13. Community Pharmacists Assisting in Total Cardiovascular Health (CPATCH): A Cluster-Randomized, Controlled Trial Testing a Focused Adherence Strategy Involving Community Pharmacies.
Blackburn DF; Evans CD; Eurich DT; Mansell KD; Jorgenson DJ; Taylor JG; Semchuk WM; Shevchuk YM; Remillard AJ; Tran DA; Champagne AP
Pharmacotherapy; 2016 Oct; 36(10):1055-1064. PubMed ID: 27581815
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
15. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Okere AN; Ezendu K; Berthe A; Diaby V
J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
[TBL] [Abstract][Full Text] [Related]
16. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Wagner M; Lindgren P; Merikle E; Goetghebeur M; Jönsson B
Can J Cardiol; 2009 Nov; 25(11):e362-9. PubMed ID: 19898698
[TBL] [Abstract][Full Text] [Related]
18. The (cost-)effectiveness of a patient-tailored intervention programme to enhance adherence to antihypertensive medication in community pharmacies: study protocol of a randomised controlled trial.
van der Laan DM; Elders PJ; Boons CC; Bosmans JE; Nijpels G; Hugtenburg JG
Trials; 2017 Jan; 18(1):29. PubMed ID: 28103948
[TBL] [Abstract][Full Text] [Related]
19. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications.
Chapman RH; Kowal SL; Cherry SB; Ferrufino CP; Roberts CS; Chen L
Value Health; 2010; 13(6):685-94. PubMed ID: 20825627
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of a medication review with follow-up service for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE program.
Jódar-Sánchez F; Malet-Larrea A; Martín JJ; García-Mochón L; López Del Amo MP; Martínez-Martínez F; Gastelurrutia-Garralda MA; García-Cárdenas V; Sabater-Hernández D; Sáez-Benito L; Benrimoj SI
Pharmacoeconomics; 2015 Jun; 33(6):599-610. PubMed ID: 25774017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
